Resistant hypertension
DOI:
https://doi.org/10.18041/2665-427X/ijeph.2.9855Keywords:
Hypertension Resistant to Conventional Therapy, Blood pressure measurement, Adherence to therapy, Secondary hypertension, Antihypertensive drugsAbstract
Introduction: Resistant arterial hypertension is a common entity that is associated with cerebrovascular accident, coronary artery disease and mortality from all associated causes, being found in studies of disease burden in 1.5%, 2.1% and 1.6%, respectively and is also related to a deterioration of renal function.
Objective: It seeks to discuss the most important aspects of the disease, starting from the definition and pathophysiology, the criteria to achieve an early, specific diagnosis, using widely available studies and finally review the appropriate management.
Results: Multiple pathophysiological and genetic factors contribute to the development of resistant arterial hypertension. Therefore, it can have different clinical phenotypes, as well as different levels of response to antihypertensive treatment. But before choosing a specific pharmacological therapy, it is essential to make the diagnosis with a blood pressure measurement technique and appropriate conditions, ruling out the presence of pseudoresistance or secondary arterial hypertension.
Conclusion: The relationship between resistant arterial hypertension with major cardiovascular events and the development of comorbidities makes it necessary to emphasize its proper diagnosis and management by trained multidisciplinary personnel.
Downloads
References
Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785-802. doi:10.1038/s41569-021-00559-8
Lamirault G, Artifoni M, Daniel M, et al. Resistant hypertension : Novel insights. Current hypertension reviews. 2020;16(1):61-72. doi:10.2174/1573402115666191011111402
Sison J, Assaad-Khalil SH, Najem R, et al. Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: The EXCITE study. Curr Med Res Opin. 2014;30(10):1937-1945. doi:10.1185/03007995.2014.942415
Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management a Scientific Statement from the American Heart Association. Vol 72.; 2018. doi:10.1161/HYP.0000000000000084
Cuenta de alto costo. Situación de la enfermedad renal crónica, la hipertensión arterial y la diabetes mellitus en Colombia 2020. Cuenta Alto Costo. 2021;152(1):1-335.
Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. Jama. 2013;310(9):959-968. doi:10.1001/jama.2013.184182
Schargrodsky H, Hernández-Hernández R, Champagne BM, et al. CARMELA: Assessment of Cardiovascular Risk in Seven Latin American Cities. Am J Med. 2008;121(1):58-65. doi:10.1016/j.amjmed.2007.08.038
Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046-1058. doi:10.1161/CIRCULATIONAHA.111.030189
Diaz KM, Booth JN, Calhoun DA, et al. Healthy Lifestyle Factors and Risk of Cardiovascular Events and Mortality in Treatment-Resistant Hypertension. Hypertension. 2014;64(3):465-471. doi:10.1161/hypertensionaha.114.03565
Borghi C, Tubach F, De Backer G, et al. Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study. Int J Cardiol. 2016;218:83-88. doi:10.1016/j.ijcard.2016.05.044
Thomas G, Xie D, Chen HY, et al. Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report from the Chronic Renal Insufficiency Cohort Study. Hypertension. 2016;67(2):387-396. doi:10.1161/HYPERTENSIONAHA.115.06487
Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlöf B, Poulter NR. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): A risk score to identify those at high-risk. J Hypertens. 2011;29(10):2004-2013. doi:10.1097/HJH.0b013e32834a8a42
Jamerson KA, Bakris GL, Dahlö B, et al. Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Press. 2007;16(2):80-86. doi:10.1080/08037050701395571
Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension. 2014;64(5):1012-1021. doi:10.1161/HYPERTENSIONAHA.114.03850
Smith SM, Gong Y, Handberg E, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32(3):635-643. doi:10.1097/HJH.0000000000000051
Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: A meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98-105. doi:10.1136/heartjnl-2018-313599
Judd K, Calhoun A, Warnock G. Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. Seminars in nephrology 2014;34(5):532-539. doi:10.1016/j.semnephrol.2014.08.007
Tishkoff SA, Reed FA, Friedlaender FR, et al. The Genetic Structure and History of Africans and African Americans. 2010;324(5930):1035-1044. doi:10.1126/science.1172257
Zilbermint M, Hannah-Shmouni F, Stratakis CA. Genetics of hypertension in African Americans and others of African descent. Int J Mol Sci. 2019;20(5):15-17. doi:10.3390/ijms20051081
Hannah-Shmouni F, Gubbi S, Spence JD, Stratakis CA, Koch CA. Resistant Hypertension: A Clinical Perspective. Endocrinol Metab Clin North Am. 2019;48(4):811-828. doi:10.1016/j.ecl.2019.08.010
Stacie D, David P, David M, Heather T, Frederick M, Karen M, Patrick O, Joe S, and Michael H. Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients. Circulation. 2012; 125(13): 1635–1642. doi:10.1161/CIRCULATIONAHA.111.068064
Calhoun DA, Schiffrin EL, Flack JM. Resistant Hypertension: An Update. Am J Hypertens. 2019;32(1):1-3. doi:10.1093/ajh/hpy156
Bourque G, Hiremath S. Rethinking Resistant Hypertension. J Clin Med. 2022;11(5). doi:10.3390/jcm11051455
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/nejmoa1511939
Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10(5):348-354. doi:10.1111/j.1751-7176.2008.07572.x
MT K, MN H, LR B, DM L. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000;15(3):90-96. http://www.libproxy.wvu.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=c8h&AN=107133513
Egan BM, Zhao Y, Li J, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62(4):691-697. doi:10.1161/HYPERTENSIONAHA.113.01448
AGREST A, PODESTA JJ, CUCURULLO A. Hiperaldosteronismo Primario. Medicina (B Aires). 1964;24:125-131.
Zehnder C. Hipertensión arterial renovascular. Rev Med Clin Condes. 2009;20(3):348-353. http://www.clinicalascondes.com/area-academica/pdf/MED_20_3/353HIPERTENSION.pdf
Williams B, Macdonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-2068. doi:10.1016/S0140-6736(15)00257-3
Krieger EM, Drager LF, Giorgi DMA, et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension the REHOT randomized study (Resistant Hypertension Optimal Treatment). Hypertension. 2018;71(4):681-690. doi:10.1161/HYPERTENSIONAHA.117.10662
Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens. 2011;24(11):1164-1180. doi:10.1038/ajh.2011.171
Armario P, Oliveras A, de la Sierra A. Hipertensión arterial resistente. Hipertens y Riesgo Vasc. 2014;31(2):58-65. doi:10.1016/j.hipert.2013.12.002
Downloads
Published
Versions
- 2023-03-09 (2)
- 2022-12-30 (1)
Issue
Section
License
Copyright (c) 2022 Interdisciplinary Journal of Epidemiology and Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
NonCommercial — You may not use the material for commercial purposes.
-
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
